Ozempic maker Novo Nordisk surges past Tesla with market value of $566B

Novo Nordisk on Thursday surpassed Tesla in market valuation after the maker of the popular weight-loss drug Wegovy and Ozempic announced positive early trial data for a highly anticipated new obesity drug.Shares surged more than 8% to record highs, shooting Novo Nordisk up in global rankings to the 12th most valuable company from 14 previously, after it told investors a Phase I trial of the pill version of experimental drug amycretin showed participants lost 13.1% of their weight after 12 weeks.That compar ...